Clinical Trials Browser

Phase 1/2 × Arginine × 90 days × Clear all

NCT07150806 2026-04-17

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Phase 1/2 Suspended

Meningioma